Association Between Anion Gap and Mortality in Critically Ill Patients with Cardiogenic Shock

Tingting Zhang¹

Jie Wang²

Xiangyang Li¹

¹Department of Clinical Laboratory, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, People's Republic of China; ²Department of Cardiology, The Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou Medical University, Wenzhou, 325000, Zhejiang, People's Republic of China

Background: No epidemiological study has determined the association between the anion gap (AG) and all-cause mortality in critically ill patients with cardiogenic shock (CS). This study was conducted to clarify the relationship between the AG and mortality in CS.

Methods: We extracted clinical data from the public database, MIMIC-III V1.4, by using a generalized additive model to identify the nonlinear relationship between the AG and the 30-day mortality in 1248 intensive care unit patients. Cox proportional hazard models were used to assess the association between the AG and the 30-day, 90-day, and 365-day mortality in CS.

Results: The AG and 30-day all-cause mortality showed a nonlinear relationship, indicated by a J-shaped curve. In the multivariate analysis, after adjusting for potential confounders, a high AG was associated with an increased risk of 30-day, 90-day, and 365-day all-cause mortality in patients with CS compared with patients who had low AG (hazard ratio [95% confidence interval] 1.62 [1.14–2.30]; 1.35 [1.04–1.84]; and 1.38 [1.03–1.84], respectively). Similar results were shown in Model I (adjusted for age, sex and ethnicity) and in Model II (fully adjusting for age, ethnicity, sex, acute kidney injury stage, CHF, renal disease, stroke, malignancy, respiratory failure, pneumonia, sodium, potassium, chloride, BUN, PT, WBC, pH, creatinine, albumin, glucose, bicarbonate, vasopressor use, diastolic blood pressure, respiration rate, temperature, the Elixhauser Comorbidity Index, SOFA score and SAPSII score).

Conclusion: The relationship between the AG and 30-day all-cause mortality followed a J-shaped curve. Higher AG was associated with an increased risk of 30-day, 90-day, and 365-day all-cause mortality in critically ill patients with CS.

Keywords: anion gap, mortality, cardiogenic shock, MIMIC-III, cohort study, Cox proportional hazard regression

Introduction

Cardiogenic shock (CS) is a clinical condition that is characterized by systemic hypotension and hypoperfusion due to insufficient cardiac output that eventually leads to multiorgan failure; CS carries risks of high morbidity and high mortality.¹ Acute myocardial infarction (MI) is the commonest cause of CS, and acute ischemic CS has a more than 50% in-hospital mortality rate.² Moreover, CS can occur as an acute manifestation of non-ischemic cardiomyopathy or as a result of severe decompensation in chronic cardiomyopathy, although these are the less frequent causes.³ Given the poor prognosis of CS in critically ill patients, researchers have sought a simple and reliable prognostic biomarker.^{4–6} However, these biomarkers have not been widely applied in clinical practice.

Correspondence: Xiangyang Li
Department of Clinical Laboratory, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, 325000, Zhejiang, People's Republic of China
Tel/Fax +86-577-88002019
Email lxywzhealth@aliyun.com

The serum anion gap (AG) is caused by the excessive production of organic acid anions and/or a proportional decrease in anion excretion.⁷ The AG is a mathematically derived parameter that can potentially be applied in the diagnosis of various metabolic acidosis.⁸ Previous studies have demonstrated that the AG is associated with mortality in several diseases, including sepsis,⁹ aortic aneurysm,¹⁰ coronary artery disease (CAD),¹¹ acute myocardial infarction (AMI),¹² chronic kidney disease (CKD),¹³ and the intensive care unit (ICU).^{14,15} Furthermore, a study has reported the prognostic value of the AG in the patient of CS requiring extracorporeal membrane oxygenation (ECMO) support.¹⁶ But no epidemiological study has explored the association between the AG and the all-cause mortality in all critically ill patients with CS. Therefore, in this study, we analyzed the data from a public clinical database with an aim to clarify the relationship between the AG and the mortality in CS.

Methods

Data Source

We used data from the Multiparameter Intelligent Monitoring in Intensive Care III version 1.4 (MIMIC-III v1.4), a public clinical critical care database.¹⁷ The database contains comprehensive, time-stamped information for more than 60,000 ICU patients (medical, surgical, coronary care and neonatal) admitted to Beth Israel Deaconess Medical Center (Boston, MA, USA) from June 1st 2001 to October 31st 2012 (single center). The data include patient demographics; dates of hospital admission, discharge, and death (in or out of the hospital); International Classification of Diseases (ICD-9) codes; physiological indices; medications; laboratory tests; chemistry; hematology; imaging; fluid balance; and others. This study was approved by the Institutional Review Boards of Beth Israel Deaconess Medical Center (Boston, MA) and the Massachusetts Institute of Technology (Cambridge, MA); a waiver of informed consent was granted.

Population-Selection Criteria

The inclusion criteria were age ≥ 18 years; CS, diagnosed using the ICD-9 code at the first ICU admission; and hospitalization in the ICU for more than 2 days. The exclusion criteria were: (1) missing data on the AG at the time of ICU admission, and (2) re-admission to the ICU.

Data Extraction

Structured Query Language (SQL) with PostgreSQL (version 9.6) was used to extract data on clinical parameters, including demographics, vital signs, laboratory tests, comorbidities, scoring systems, etc., within the first 24 h after the ICU admission. The comorbidities that were extracted included CAD, congestive heart failure (CHF), atrial fibrillation (AFIB), stroke, renal disease, liver disease, pneumonia, malignancy, respiratory failure, and acute respiratory distress syndrome (ARDS). The laboratory tests included the levels of AG, albumin, bicarbonate, bilirubin, creatinine, chloride, glucose, hematocrit, hemoglobin, platelet, sodium, potassium, lactate, blood urea nitrogen (BUN), white blood cell (WBC), prothrombin time (PT), activated partial thromboplastin time (APTT), and the international normalized ratio (INR).

Furthermore, the Sequential Organ Failure Assessment (SOFA) score¹⁸ and the Simplified Acute Physiology Scores II (SAPSII)¹⁹ were obtained. In addition, we extracted data on age, sex, ethnicity, systolic blood pressure (SBP), diastolic blood pressure (DBP), mean blood pressure (MBP), heart rate, respiratory rate, temperature, and SPO₂, renal replacement therapy (RRT), vasopressor use, and the length of stay in the ICU as well as in the hospital. Information on the survival status was obtained from the Social Security Death Index records. The end-points of our study were the 30-day, 90-day, and 365-day all-cause mortality from the date of ICU admission.

Statistical Analysis

Continuous variables are presented as the mean $\pm$ standard deviation (SD) or the median and interquartile range (IQR). Categorical data are summarized as frequencies or percentages. We used the chi-square, one-way ANOVA, and Kruskal–Wallis *H*-tests to determine significant differences between the means and proportions among the study groups. We used a generalized additive model to identify the non-linear relationship between the AG and the 30-day mortality. In addition, we used Cox proportional hazards models to assess the association between the AG and the 30-day, 90-day, and 365-day mortality in CS, and presented the results from the unadjusted, minimally adjusted, and fully adjusted analyses. The results are presented as hazard ratios (HR) with 95% confidence intervals (CI). Basic characteristics of population (age, sex and ethnicity) were chosen as minimally adjusted confounders. Fully adjusted confounders were selected based on a more

than 10% change in the effect estimate.²⁰ Subgroup analysis of the associations between the AG and the 30-day all-cause mortality was performed using stratified linear regression models. The modifications and interactions of the subgroups were analyzed using likelihood ratio tests. All probability values were two-sided, and values less than 0.05 were considered statistically significant. R (<http://www.R-project.org>) and EmpowerStats (<http://www.empowerstats.cn/>), X&Y solutions, Inc, Boston, MA) were used for all statistical analyses.

Results

Characteristics of Participants

A total of 1248 ICU patients met the inclusion criteria. The baseline characteristics of the participants are summarized in Table 1; participants were grouped into quartiles by the AG. The participants of this study were generally older, mostly male, White patients. In the study subgroup with a higher AG (Q4), the patients were more likely to have hypotension, and to report a comorbidity of renal disease, with significantly higher values for the heart rate, creatinine, glucose, hematocrit, potassium, lactate, BUN, WBC, PT, APTT, INR, SOFA, SAPSII, renal replacement therapy, vasopressor use, and mortality.

Relationship Between the AG and Mortality

We found that the relationship between the AG and the 30-day all-cause mortality was non-linear, as shown by a J-shaped curve (Figure 1). To further evaluate the associations between the AG and the 30-day, 90-day, and 365-day all-cause mortality in patients with CS, a Cox proportional hazards regression model was used. We stratified the AG by quartiles and have shown the adjusted models in Table 2. In Model I (adjusted for age, sex, and ethnicity), a higher AG was associated with an increased risk of all-cause mortality. After fully adjusting for age, ethnicity, sex, acute kidney injury stage, CHF, renal disease, stroke, malignancy, respiratory failure, pneumonia, sodium, potassium, chloride, BUN, PT, WBC, pH, creatinine, albumin, glucose, bicarbonate, vasopressor use, diastolic blood pressure, respiration rate, temperature, the Elixhauser Comorbidity Index, SOFA score, and SAPSII score in Model II, the high AG remained a significant predictor of 30-day, 90-day, and 365-day all-cause mortality

compared with low AG (HR [95% CI], 1.62 [1.14–2.30]; 1.35 [1.04–1.84]; and 1.38 [1.03–1.84], respectively). Furthermore, for the sensitivity analysis, we considered the AG as a categorical variable, and observed the same trends (*p* for trends: <0.0001, 0.0010, and 0.0015 for the 30-day, 90-day, and 365-day all-cause mortality, respectively).

Subgroup Analyses

The results of the subgroup analysis of the associations between the AG and the 30-day all-cause mortality is shown in Table 3. The test for interactions was not statistically significant in most of the strata. Significant interactions were observed for ethnicity, CAD, bilirubin, hematocrit, hemoglobin, chloride, respiratory rate, and RRT (*P* < 0.05). Among these strata, patients with a higher AG exhibited significantly higher mortality, especially with regard to chloride ≥ 102 mmol/L and a respiratory rate ≥ 20 beats/minute. A similar trend was observed in White patients and those with CAD.

Discussion

Our study demonstrated a J-shaped, nonlinear relationship between the AG and the 30-day all-cause mortality. After adjusting for covariates, a higher AG was associated with an increased risk of 30-day, 90-day, and 365-day all-cause mortality in critically ill patients with CS. Furthermore, after adjusting for additional confounding factors, a higher AG remained a significant predictor of all-cause mortality. High AG is associated with higher mortality in the multivariate model and the overall trend in the quartiles was statistically significant are match to the J-shape curve. It shows that the mortality of CS patients increases with the increase of AG level, and it is more obvious when the AG level is higher.

The AG is an applied mathematically derived parameter that has been used for more than 50 years and is the simplest method for the evaluation of patients based on the acid–base status, which is calculated as the difference between the measured serum cation and anion concentrations.⁷ Traditionally, the AG is one of the most commonly used biomarkers, and this parameter is routinely determined in all patients who are admitted to the ICU. Calculating the AG of critically ill patients is considered a sensitive and specific tool for predicting the prognosis or mortality risk.^{21,22}

Table I Baseline Characteristics of the Study Patients According to Anion Gap (N =1248)

Characteristic	Anion Gap, mmol/L				P value
	Q1 (<12)	Q2 (≥12-<14)	Q3 (≥14-<17)	Q4 (≥17)	
Age, years	71.4 ± 12.7	70.4 ± 13.1	69.7 ± 14.4	72.1 ± 14.4	0.050
Gender, n (%)					0.751
Female	90 (41.9)	114 (39.3)	159 (39.8)	148 (43.0)	
Male	125 (58.1)	176 (60.7)	240 (60.2)	196 (57.0)	
Ethnicity, n (%)					0.664
White	151 (70.2)	203 (70.0)	275 (68.9)	226 (65.7)	
Black	17 (7.9)	17 (5.9)	28 (7.0)	21 (6.1)	
Other	47 (21.9)	70 (24.1)	96 (24.1)	97 (28.2)	
SBP, mmHg	106.1 ± 11.7	104.5 ± 12.3	104.6 ± 13.4	100.3 ± 14.9	<0.001
DBP, mmHg	56.7 ± 9.3	58.0 ± 10.2	57.9 ± 9.9	55.7 ± 10.6	<0.001
MBP, mmHg	73.2 ± 7.9	74.2 ± 9.4	74.2 ± 9.8	70.7 ± 11.2	0.029
Heart rate, beats/minute	88.1 ± 15.6	88.0 ± 16.9	90.5 ± 17.4	90.4 ± 17.6	0.073
Respiratory rate, beats/minute	19.1 ± 3.8	19.7 ± 4.1	20.4 ± 4.1	20.9 ± 4.3	<0.001
Temperature, °C	36.7 ± 0.7	36.8 ± 0.8	36.8 ± 0.9	36.5 ± 1.0	<0.001
SPO ₂ , %	97.1 ± 3.8	97.1 ± 2.5	96.7 ± 3.2	94.7 ± 7.1	<0.001
Comorbidities, n (%)					
Coronary artery disease	134 (62.3)	172 (59.3)	230 (57.6)	169 (49.1)	0.008
Congestive heart failure	96 (44.7)	119 (41.0)	169 (42.4)	143 (41.6)	0.861
Atrial fibrillation	97 (45.1)	149 (51.4)	174 (43.6)	168 (48.8)	0.184
Stroke	14 (6.5)	16 (5.5)	19 (4.8)	14 (4.1)	0.604
Renal disease	41 (19.1)	46 (15.9)	81 (20.3)	108 (31.4)	<0.001
Liver disease	7 (3.3)	11 (3.8)	10 (2.5)	10 (2.9)	0.802
Pneumonia	76 (35.3)	92 (31.7)	136 (34.1)	99 (28.8)	0.322
Malignancy	29 (13.5)	34 (11.7)	37 (9.3)	37 (10.8)	0.431
Respiratory failure	108 (50.2)	143 (49.3)	209 (52.4)	153 (44.5)	0.189
ARDS	3 (1.4)	5 (1.7)	11 (2.8)	4 (1.2)	0.394
Laboratory parameters					
Anion gap, mmol/L	10.1 ± 1.2	12.6 ± 0.5	14.9 ± 0.8	19.9 ± 3.6	<0.001
Albumin, g/dL	3.0 ± 0.7	3.0 ± 0.7	3.1 ± 0.6	3.2 ± 0.6	0.009
Bicarbonate, mg/dL	21.9 ± 5.2	20.8 ± 4.9	19.8 ± 4.4	16.8 ± 4.9	<0.001
Bilirubin, mg/dL	1.4 ± 2.6	1.1 ± 1.2	0.9 ± 1.8	1.4 ± 2.9	<0.001
Creatinine, mEq/L	1.1 ± 0.6	1.2 ± 0.7	1.6 ± 1.0	2.8 ± 2.1	<0.001
Chloride, mmol/L	102.9 ± 6.6	102.6 ± 5.4	101.2 ± 6.1	99.3 ± 6.3	<0.001
Glucose, mg/dL	105.8 ± 32.9	118.2 ± 42.6	127.8 ± 49.1	133.9 ± 70.0	<0.001
Hematocrit, %	28.1 ± 6.2	29.4 ± 6.1	30.9 ± 6.5	30.3 ± 6.7	<0.001
Hemoglobin, g/dL	9.4 ± 2.0	10.0 ± 2.2	10.4 ± 2.3	10.0 ± 2.2	<0.001
Platelet, 10 ⁹ /L	173.3 ± 82.9	188.7 ± 104.8	214.2 ± 107.1	208.7 ± 113.1	<0.001
Sodium, mmol/L	135.8 ± 4.6	135.6 ± 4.6	135.1 ± 5.3	134.4 ± 5.2	0.007
Potassium, mmol/L	3.6 ± 0.5	3.7 ± 0.5	3.8 ± 0.6	4.0 ± 0.7	<0.001
Lactate, mmol/L	1.7 ± 1.2	2.0 ± 1.4	2.1 ± 1.3	3.6 ± 2.8	<0.001
BUN, mg/dL	24.0 ± 13.8	25.6 ± 14.0	34.6 ± 21.4	48.8 ± 28.1	<0.001
WBC, 10 ⁹ /L	10.6 ± 11.0	10.7 ± 4.7	12.0 ± 5.2	12.8 ± 6.6	<0.001
PT, second	15.5 ± 4.9	15.8 ± 7.6	15.7 ± 5.4	18.3 ± 9.4	<0.001
APTT, second	36.0 ± 16.9	37.7 ± 18.7	38.4 ± 19.1	44.7 ± 27.5	<0.001
INR	1.4 ± 0.6	1.5 ± 1.0	1.5 ± 0.6	2.0 ± 1.8	<0.001

(Continued)

Table I (Continued).

Characteristic	Anion Gap, mmol/L				P value
	Q1 (<12)	Q2 (≥12-<14)	Q3 (≥14-<17)	Q4 (≥17)	
Scoring systems					
SOFA	6.5 ± 3.4	6.2 ± 3.6	6.5 ± 3.4	8.7 ± 3.6	<0.001
SAPSII	43.8 ± 12.4	43.5 ± 14.9	45.4 ± 14.3	55.2 ± 15.1	<0.001
AKI stage, n (%)					<0.001
Stage 1	41 (19.1)	34 (11.7)	48 (12.1)	44 (12.8)	
Stage 2	53 (24.7)	69 (23.8)	76 (19.1)	34 (9.9)	
Stage 3	113 (52.6)	162 (55.9)	253 (63.6)	242 (70.3)	
Renal replacement therapy, n (%)	23 (10.7)	27 (9.3)	59 (14.8)	94 (27.3)	<0.001
Vasopressor use, n (%)	167 (77.7)	235 (81.0)	321 (80.5)	293 (85.2)	0.140
ICU LOS, day	8.3 ± 9.2	7.7 ± 7.9	8.4 ± 8.8	7.3 ± 12.2	<0.001
Hospital LOS, day	15.5 ± 12.9	15.4 ± 16.7	15.3 ± 13.6	12.6 ± 17.0	<0.001
30-day mortality, n (%)	65 (30.2)	82 (28.3)	143 (35.8)	223 (64.8)	<0.001
90-day mortality, n (%)	95 (44.2)	106 (36.6)	175 (43.9)	242 (70.3)	<0.001
365-day mortality, n (%)	106 (49.3)	138 (47.6)	198 (49.6)	265 (77.0)	<0.001

Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; MBP, mean blood pressure; ARDS, acute respiratory distress syndrome; BUN, blood urea nitrogen; WBC, white blood cell; PT, prothrombin time; APTT, activated partial thromboplastin time; INR, international normalized ratio; SOFA, Sequential Organ Failure Assessment; SAPSII, Simplified Acute Physiology Score II; AKI, acute kidney injury; ICU, intensive care unit; LOS, length of stay.

Previous studies reported that an increase in the AG may have prognostic significance in several diseases.^{9–11,23} In this study, a U-shaped relationship was

Figure 1 Association between anion gap and 30-day all-cause mortality. A threshold, nonlinear association between anion gap and 30-day all-cause mortality was found in a generalized additive mode. Solid red line represents the smooth curve fit between variables. Imaginary lines represent the 95% of confidence interval from the fit.

observed with regard to AG and the all-cause mortality, and the AG was identified as a significant predictor of poor prognosis in CS patients after adjusting for relevant confounding factors.

Due to the insufficient cardiac output, CS constitutes a clinical syndrome of systemic hypotension and hypoperfusion that causes multiorgan failure, which manifests as oliguria, lactic acidosis, hyperpigmentation, and clammy limbs.²⁴ An elevated serum AG is usually caused by the excessive production of organic acid anions and/or a concomitant decrease in anion excretion,⁷ wherein the lactic acid level and ketoanions are important factors.²⁵ A possible mechanism is that the metabolic rate of patients with CS is significantly increased, with consequent sympathetic activation, accelerated glycolysis, and increased lactate levels; patients with heart failure and acute coronary syndrome have significantly elevated levels of blood ketone bodies.^{26–28} Furthermore, CS patients often have concomitant impairment of glomerular filtration function, which results in the retention of non-chlorine anions due to the accumulation of acidic substances.¹³ All of these data strongly suggest that higher AG might be associated with the prognosis of patients with CS;

Table 2 Relationship Between Anion Gap and All-Cause Mortality in Different Models

Variable	Crude Model		Model I		Model II	
	HR (95% CIs)	P value	HR (95% CIs)	P value	HR (95% CIs)	P value
30-day all-cause mortality						
Anion gap, mmol/L	1.12 (1.11, 1.14)	<0.0001	1.13 (1.11, 1.15)	<0.0001	1.07 (1.04, 1.10)	<0.0001
Anion gap (Quartile), mmol/L						
<12	1.0(ref)		1.0(ref)		1.0(ref)	
≥12, <14	0.97 (0.70, 1.34)	0.8524	1.03 (0.74, 1.42)	0.8652	0.82 (0.58, 1.15)	0.2496
≥14, <17	1.25 (0.94, 1.68)	0.1296	1.32 (0.99, 1.77)	0.0612	0.96 (0.70, 1.32)	0.7923
≥17	3.13 (2.37, 4.13)	<0.0001	3.18 (2.41, 4.20)	<0.0001	1.62 (1.14, 2.30)	0.0068
P for trend	<0.0001		<0.0001		<0.0001	
90-day all-cause mortality						
Anion gap, mmol/L	1.12 (1.10, 1.13)	<0.0001	1.12 (1.11, 1.14)	<0.0001	1.06 (1.03, 1.09)	<0.0001
Anion gap (Quartile), mmol/L						
<12	1.0(ref)		1.0(ref)		1.0(ref)	
≥12, <14	0.84 (0.64, 1.11)	0.2206	0.90 (0.68, 1.18)	0.4409	0.74 (0.55, 1.02)	0.0813
≥14, <17	1.05 (0.82, 1.35)	0.7062	1.12 (0.87, 1.44)	0.3741	0.80 (0.61, 1.05)	0.1125
≥17	2.43 (1.92, 3.09)	<0.0001	2.51 (1.97, 3.18)	<0.0001	1.35 (1.04, 1.84)	0.0429
P for trend	<0.0001		<0.0001		0.0010	
365-day all-cause mortality						
Anion gap, mmol/L	1.11 (1.10, 1.13)	<0.0001	1.12 (1.10, 1.14)	<0.0001	1.05 (1.03, 1.08)	0.0001
Anion gap (Quartile), mmol/L						
<12	1.0(ref)		1.0(ref)		1.0(ref)	
≥12, <14	0.97 (0.75, 1.25)	0.8116	1.03 (0.80, 1.33)	0.8250	0.86 (0.66, 1.12)	0.2651
≥14, <17	1.06 (0.84, 1.34)	0.6422	1.13 (0.89, 1.43)	0.3045	0.81 (0.63, 1.05)	0.1129
≥17	2.47 (1.97, 3.10)	<0.0001	2.55 (2.04, 3.20)	<0.0001	1.38 (1.03, 1.84)	0.0303
P for trend	<0.0001		<0.0001		0.0015	

Notes: Models were derived from Cox proportional hazards regression models. Crude model adjust for: none. Adjust I model adjust for: age, ethnicity and gender. Adjust II model adjust for: age, ethnicity, gender, acute kidney injury stage, congestive heart failure, renal disease, stroke, malignancy, respiratory failure, pneumonia, sodium, potassium, chloride, BUN, PT, WBC, PH, creatinine, albumin, glucose, bicarbonate, vasopressor use, diastolic blood pressure, respiration rate, temperature, Elixhauser index, SOFA, SAPSII.

Abbreviations: HR, hazard ratio; CI, confidence interval.

therefore, the results of this study support the above-mentioned hypothesis.

Furthermore, McDonald, C.I. et al had reported the prognostic value of the AG in the patient of CS requiring ECMO support.¹⁶ But our study has explored the association between the AG and the all-cause mortality in all critically ill patients with CS which mean our study covered a wider population and applied to a wider range of people.

There are a few limitations of our study. First, as this was a retrospective analysis, the analysis is subject to selection bias. Second, the ICD-9 code for CS was used for diagnosis which may lead to bias. Third, we extracted the AG data for patients only based on the

test upon their admission to the ICU and did not determine the trends of the changes in the AG, which may influence the reliability of the results. Fourth, as information on prognostic factors, such as cardiac troponin levels, was not available for some patients in the database, we were unable to calibrate all of the relevant confounders. Finally, this was an observational study and, therefore, we could not confirm the potential mechanism of action whereby a higher AG was related to the severity and prognosis of CS.

Conclusions

The relationship between the AG and 30-day all-cause mortality followed a J-shaped curve. Higher AG was

Table 3 Subgroup Analysis of the Associations Between Anion Gap and 30-Day All-Cause Mortality

Characteristic	N	HR (95% CI)	P value	P for Interaction
Age, years				0.2008
<72.9	621	1.14 (1.11, 1.17)	<0.0001	
≥72.9	627	1.12 (1.10, 1.15)	<0.0001	
Gender				0.6247
Female	511	1.12 (1.09, 1.14)	<0.0001	
Male	737	1.13 (1.11, 1.15)	<0.0001	
Ethnicity				0.0041
White	855	1.16 (1.13, 1.19)	<0.0001	
Black	83	1.07 (1.00, 1.14)	0.0491	
Other	310	1.11 (1.08, 1.14)	<0.0001	
CHF				0.7634
No	721	1.13 (1.10, 1.15)	<0.0001	
Yes	527	1.14 (1.11, 1.18)	<0.0001	
CAD				<0.0001
No	543	1.10 (1.07, 1.12)	<0.0001	
Yes	705	1.19 (1.15, 1.22)	<0.0001	
AFIB				0.4855
No	660	1.13 (1.11, 1.16)	<0.0001	
Yes	588	1.13 (1.10, 1.16)	<0.0001	
Renal disease				0.0383
No	972	1.15 (1.12, 1.18)	<0.0001	
Yes	276	1.11 (1.08, 1.15)	<0.0001	
Liver disease				0.6737
No	1210	1.13 (1.11, 1.15)	<0.0001	
Yes	38	1.10 (0.95, 1.27)	0.2030	
Stroke				0.4105
No	1185	1.13 (1.11, 1.15)	<0.0001	
Yes	63	1.25 (1.04, 1.49)	0.0166	
Pneumonia				0.0698
No	845	1.14 (1.12, 1.16)	<0.0001	
Yes	403	1.11 (1.06, 1.15)	<0.0001	
Respiratory failure				0.0517
No	635	1.15 (1.12, 1.17)	<0.0001	
Yes	613	1.12 (1.09, 1.15)	<0.0001	
ARDS				0.3866
No	1225	1.14 (1.12, 1.16)	<0.0001	
Yes	23	1.04 (0.90, 1.20)	0.5706	
Malignancy				0.9078
No	1111	1.14 (1.12, 1.16)	<0.0001	
Yes	137	1.16 (1.10, 1.22)	<0.0001	
Albumin, g/dL				0.0812
<3.1	315	1.10 (1.07, 1.13)	<0.0001	
≥3.1	384	1.16 (1.11, 1.21)	<0.0001	

(Continued)

Table 3 (Continued).

Characteristic	N	HR (95% CI)	P value	P for Interaction
Bicarbonate, mg/dL				0.4811
<20	597	1.11 (1.09, 1.14)	<0.0001	
≥20	651	1.14 (1.09, 1.19)	<0.0001	
Bilirubin, mg/dL				0.0259
<0.7	418	1.14 (1.09, 1.19)	<0.0001	
≥0.7	441	1.13 (1.10, 1.15)	<0.0001	
Sodium, mmol/L				0.1491
<135	502	1.12 (1.09, 1.15)	<0.0001	
≥135	746	1.15 (1.12, 1.17)	<0.0001	
Potassium, mmol/L				0.1660
<3.7	562	1.15 (1.11, 1.20)	<0.0001	
≥3.7	686	1.13 (1.11, 1.15)	<0.0001	
Lactate, mmol/L				0.5146
<1.8	465	1.10 (1.05, 1.16)	0.0001	
≥1.8	494	1.10 (1.08, 1.13)	<0.0001	
BUN, mg/dL				0.1278
<27	591	1.14 (1.10, 1.18)	<0.0001	
≥27	657	1.12 (1.10, 1.15)	<0.0001	
PT, second				0.0816
<14.5	604	1.15 (1.10, 1.20)	<0.0001	
≥14.5	606	1.12 (1.10, 1.14)	<0.0001	
INR				0.0708
<1.3	498	1.17 (1.11, 1.23)	<0.0001	
≥1.3	713	1.12 (1.10, 1.14)	<0.0001	
APTT, second				0.7576
<32.9	610	1.12 (1.07, 1.16)	<0.0001	
≥32.9	606	1.13 (1.11, 1.15)	<0.0001	
WBC, 10 ⁹ /L				0.6960
<10.8	624	1.12 (1.09, 1.15)	<0.0001	
≥10.8	622	1.15 (1.12, 1.18)	<0.0001	
Platelet, 10 ⁹ /L				0.1366
<184	620	1.12 (1.09, 1.14)	<0.0001	
≥184	627	1.18 (1.14, 1.22)	<0.0001	
Hematocrit, %				0.0157
<29.6	619	1.11 (1.08, 1.13)	<0.0001	
≥29.6	629	1.19 (1.15, 1.23)	<0.0001	
Hemoglobin, g/dL				0.0100
<9.9	602	1.11 (1.09, 1.14)	<0.0001	
≥9.9	645	1.19 (1.15, 1.23)	<0.0001	
Creatinine, mEq/L				0.3452
<1.3	605	1.11 (1.06, 1.16)	<0.0001	
≥1.3	643	1.13 (1.10, 1.15)	<0.0001	

(Continued)

Table 3 (Continued).

Characteristic	N	HR (95% CI)	P value	P for Interaction
Glucose, mg/dL				0.1169
<114	616	1.12 (1.10, 1.15)	<0.0001	
≥114	632	1.15 (1.12, 1.18)	<0.0001	
Chloride, mmol/L				0.0027
<102	611	1.11 (1.09, 1.14)	<0.0001	
≥102	637	1.17 (1.14, 1.20)	<0.0001	
SBP, mmHg				0.4507
<103	621	1.13 (1.11, 1.15)	<0.0001	
≥103	621	1.13 (1.08, 1.17)	<0.0001	
DBP, mmHg				0.0629
<57	620	1.14 (1.12, 1.17)	<0.0001	
≥57	622	1.12 (1.09, 1.15)	<0.0001	
MBP, mmHg				0.0626
<72	619	1.14 (1.12, 1.17)	<0.0001	
≥72	624	1.10 (1.07, 1.14)	<0.0001	
Heart rate, beats/minute				0.2923
<89	621	1.14 (1.11, 1.17)	<0.0001	
≥89	622	1.13 (1.11, 1.16)	<0.0001	
Respiratory rate, beats/minute				0.0195
<20	617	1.12 (1.08, 1.17)	<0.0001	
≥20	626	1.13 (1.10, 1.15)	<0.0001	
Temperature, °C				0.2451
<36.7	593	1.13 (1.10, 1.16)	<0.0001	
≥36.7	599	1.16 (1.12, 1.20)	<0.0001	
SPO ₂ , %				0.4524
<97	620	1.14 (1.11, 1.16)	<0.0001	
≥97	620	1.13 (1.09, 1.17)	<0.0001	
SOFA score				0.6956
<7	556	1.10 (1.05, 1.16)	0.0003	
≥7	692	1.12 (1.10, 1.14)	<0.0001	
SAPSII score				0.6197
<46	594	1.12 (1.06, 1.18)	<0.0001	
≥46	654	1.11 (1.09, 1.13)	<0.0001	
Vasopressor use				0.3629
No	232	1.09 (1.01, 1.18)	0.0213	
Yes	1016	1.13 (1.11, 1.15)	<0.0001	
RRT				0.0001
No	1045	1.14 (1.12, 1.17)	<0.0001	
Yes	203	1.07 (1.03, 1.11)	0.0012	

Abbreviations: CHF, congestive heart failure; CAD, coronary artery disease; AFIB, atrial fibrillation; ARDS, acute respiratory distress syndrome; BUN, blood urea nitrogen; PT, prothrombin time; INR, international normalized ratio; APTT, activated partial thromboplastin time; WBC, white blood cell; SBP, systolic blood pressure; DBP, diastolic blood pressure; MBP, mean blood pressure; SOFA, Sequential Organ Failure Assessment; SAPSII, Simplified Acute Physiology Score II; RRT, renal replacement therapy.

associated with an increased risk of 30-day, 90-day, and 365-day all-cause mortality in critically ill patients with CS.

Acknowledgments

We would like to thank Dr. Su gaofan for editorial help.

Funding

There is no funding to report.

Disclosure

The authors report no conflicts of interest in this work.

References

1. van Diepen S, Katz JN, Albert NM, et al. Contemporary Management of cardiogenic shock: a scientific statement from the American heart association. *Circulation*. 2017;136(16):e232–e268. doi:10.1161/CIR.0000000000000525
2. Goldberg RJ, Spencer FA, Gore JM, et al. Thirty-year trends (1975 to 2005) in the magnitude of, management of, and hospital death rates associated with cardiogenic shock in patients with acute myocardial infarction: a population-based perspective. *Circulation*. 2009;119(9):1211–1219. doi:10.1161/CIRCULATIONAHA.108.814947
3. Gheorghiadu M, Pang PS. Acute heart failure syndromes. *J Am Coll Cardiol*. 2009;53(7):557–573. doi:10.1016/j.jacc.2008.10.041
4. Sleeper LA, Reynolds HR, White HD, et al. A severity scoring system for risk assessment of patients with cardiogenic shock: a report from the SHOCK Trial and Registry. *Am Heart J*. 2010;160(3):443–450. doi:10.1016/j.ahj.2010.06.024
5. Thiele H, Zeymer U, Neumann F-J, et al. Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial. *Lancet*. 2013;382(9905):1638–1645. doi:10.1016/S0140-6736(13)61783-3
6. Link A, Pösch J, Rbahr R, et al. Circulating angiopoietins and cardiovascular mortality in cardiogenic shock. *Eur Heart J*. 2013;34(22):1651–1662. doi:10.1093/eurheartj/ehs487
7. Kraut JA, Madias NE. Serum anion gap: its uses and limitations in clinical medicine. *Clin J Am Soc Nephrol*. 2007;2(1):162–174. doi:10.2215/CJN.03020906
8. Kraut JA, Nagami GT. The serum anion gap in the evaluation of acid-base disorders: what are its limitations and can its effectiveness be improved? *Clin J Am Soc Nephrol*. 2013;8(11):2018–2024. doi:10.2215/CJN.04040413
9. Mohr NM, Vakkalanka JP, Faine BA, et al. Serum anion gap predicts lactate poorly, but may be used to identify sepsis patients at risk for death: a cohort study. *J Crit Care*. 2018;44:223–228. doi:10.1016/j.jcrc.2017.10.043
10. Chen Q, Chen Q, Li L, et al. Serum anion gap on admission predicts intensive care unit mortality in patients with aortic aneurysm. *Exp Ther Med*. 2018;16(3):1766–1777.
11. Yang SW, Zhou YJ, Zhao YX, et al. The serum anion gap is associated with disease severity and all-cause mortality in coronary artery disease. *J Geriatr Cardiol*. 2017;14(6):392–400.
12. Sahu A, Cooper HA, Panza JA. The initial anion gap is a predictor of mortality in acute myocardial infarction. *Coron Artery Dis*. 2006;17(5):409–412. doi:10.1097/00019501-200608000-00002
13. Abramowitz MK, Hostetter TH, Melamed ML. The serum anion gap is altered in early kidney disease and associates with mortality. *Kidney Int*. 2012;82(6):701–709. doi:10.1038/ki.2012.196

14. Kim MJ, Kim YH, Sol IS, et al. Serum anion gap at admission as a predictor of mortality in the pediatric intensive care unit. *Sci Rep*. 2017;7(1):1456. doi:10.1038/s41598-017-01681-9
15. Glasmacher SA, Stones W. Anion gap as a prognostic tool for risk stratification in critically ill patients - a systematic review and meta-analysis. *BMC Anesthesiol*. 2016;16(1):68. doi:10.1186/s12871-016-0241-y
16. McDonald CI, Brodie D, Schmidt M, et al. Elevated venous to arterial carbon dioxide gap and anion gap are associated with poor outcome in cardiogenic shock requiring extracorporeal membrane oxygenation support. *Asaio j*. 2021;67(3):263–269. doi:10.1097/MAT.0000000000001215
17. Johnson AE, Pollard TJ, Shen L, et al. MIMIC-III, a freely accessible critical care database. *Sci Data*. 2016;3:160035. doi:10.1038/sdata.2016.35
18. Allard J. SOFA—an open source framework for medical simulation. *Stud Health Technol Inform*. 2007;125:13–18.
19. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. *JAMA*. 1993;270(24):2957–2963. doi:10.1001/jama.1993.03510240069035
20. Agoritsas T, Merglen A, Shah ND, et al. Adjusted Analyses in studies addressing therapy and harm: users' guides to the medical literature. *JAMA*. 2017;317(7):748–759. doi:10.1001/jama.2016.20029
21. Kaneko M, Hagiwara S, Aoki M, et al. The significance of strong ion gap for predicting return of spontaneous circulation in patients with cardiopulmonary arrest. *Open Med*. 2017;12(1):33–38. doi:10.1515/med-2017-0006
22. Ho KM, Lan NSH, Williams TA, et al. A comparison of prognostic significance of strong ion gap (SIG) with other acid-base markers in the critically ill: a cohort study. *J Intensive Care*. 2016;4(1):43. doi:10.1186/s40560-016-0166-z
23. Taylor EN, Forman JP, Farwell WR. Serum anion gap and blood pressure in the national health and nutrition examination survey. *Hypertension*. 2007;50(2):320–324. doi:10.1161/HYPERTENSIONAHA.107.092643
24. Califf RM, Bengtson JR. Cardiogenic shock. *N Engl J Med*. 1994;330(24):1724–1730. doi:10.1056/NEJM199406163302406
25. Gabow PA, Kaehny WD, Fennessey PV, et al. Diagnostic importance of an increased serum anion gap. *N Engl J Med*. 1980;303(15):854–858. doi:10.1056/NEJM198010093031505
26. Lazzeri C, Valente S, Chiofalo M, et al. Clinical significance of lactate in acute cardiac patients. *World J Cardiol*. 2015;7(8):483–489. doi:10.4330/wjc.v7.i8.483
27. Lommi J, Kupari M, Koskinen P, et al. Blood ketone bodies in congestive heart failure. *J Am Coll Cardiol*. 1996;28(3):665–672. doi:10.1016/0735-1097(96)00214-8
28. Bedi KC, Snyder NW, Brandimarto J, et al. Evidence for Intramyocardial disruption of lipid metabolism and increased myocardial ketone utilization in advanced human heart failure. *Circulation*. 2016;133(8):706–716. doi:10.1161/CIRCULATIONAHA.115.017545

International Journal of General Medicine

Dovepress

Publish your work in this journal

The International Journal of General Medicine is an international, peer-reviewed open-access journal that focuses on general and internal medicine, pathogenesis, epidemiology, diagnosis, monitoring and treatment protocols. The journal is characterized by the rapid reporting of reviews, original research and clinical studies

across all disease areas. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/international-journal-of-general-medicine-journal>